RIYADH, Saudi Arabia, Dec. 12, 2023 — Lendo, a Saudi Arabia-based shariah-compliant debt crowdfunding marketplace, has raised SAR 105 million ($28 million) in Series B funding led by Sanabil Investments, a wholly-owned company by the Public Investment Fund (“PIF”). The round saw participation from Shorooq Partners, AB Ventures and other investors.

Lendo is a shariah-compliant, debt crowdfunding marketplace that helps pre-finance outstanding invoices for businesses in Saudi Arabia. The platform is a community of creditworthy borrowers and sophisticated investors looking for alternative investments. The platform is licensed by the Saudi Central Bank (SAMA). Lendo will use the funds to support its fast-growing customer base in Saudi Arabia which has grown 3X year-on-year, introduce more innovative financing products, and accelerate market expansion plans.

“With this funding round, we are going to expand into new markets, support new and current customers and launch new Shariah-compliant products, all the while continuing to innovate the marketplace for digital lending. We are going to make financial services more accessible, affordable, and inclusive for everyone. I am excited to see what the future holds for our company,” said Osama Alraee, CEO, and co-founder of Lendo, who also disclosed its plans for an IPO within the next few years.

Alraee has also expressed his gratitude to SAMA (Saudi Central Bank), Fintech Saudi, MCIT, Misk, and Monshaat for their unwavering support, emphasizing the pivotal role they have played in advancing financial inclusivity and fostering innovation in partnership with Lendo to reshape the financial landscape. Their dedicated efforts in advancing financial inclusivity and fostering innovation have been invaluable to us. We greatly appreciate their partnership in our mission to transform the financial landscape.

“The growing demand for alternative, agile, and accessible lending solutions presents a significant opportunity. At Lendo, we are well-positioned to lead the charge in promoting financial inclusion not only in Saudi Arabia but also beyond. By fueling SME growth, we aim to contribute to the realization of Saudi Arabia’s Vision 2030 economic goals and to create a ripple effect of opportunity throughout the MENA region,” said Mohamed Jawabri, COO, and co-Founder of Lendo.

For the full press release, please visit Lendo News page

SOURCE Lendo

SAN FRANCISCO, Dec. 12, 2023 — Extropic, a pioneering force in the realm of physics-based artificial intelligence (AI), proudly announces the successful completion of its $14.1 million Seed round. Led by Steve Jang and Kindred Ventures, renowned for their contributions to Uber, Coinbase, and Humane, the funding round features prominent participants such as Buckley Ventures, HOF Capital, Julian Capital, Marque VC, OSS Capital, Valor Equity Partners, Weekend Fund, and a host of distinguished angel investors.

Redefining the Landscape of Computation
Extropic is at the forefront of a groundbreaking initiative to redefine computation through a novel full-stack paradigm of physics-based computing. In a world where the demand for scalable, cost-effective, and efficient computing is skyrocketing with the rise of generative AI, Extropic envisions a future where computers leverage the natural entropy of the world as an asset, program themselves to learn representations of the world, and operate with unprecedented efficiency.

Harnessing the Power of Thermodynamics
Extropic’s computing paradigm is built on the principles of out-of-equilibrium thermodynamics, aiming to seamlessly merge generative AI with the fundamental physics of the world. The goal is to achieve the ultimate embedding of generative AI into physical processes, pushing the limits of efficiency defined by the laws of physics in terms of space, time, and energy.

Meet the Visionaries Behind Extropic
Extropic was founded in 2022 by Guillaume Verdon, Extropic CEO, a pioneer in quantum deep learning and former quantum tech lead within the Physics & AI team at Alphabet’s X. The team also includes Trevor McCourt, Extropic CTO, and Christopher Chamberland, Extropic Principal Architect, both recognized for their significant contributions to the field of quantum computing.

Interdisciplinary Team with Extensive Experience
Extropic’s team comprises scientists and engineers with backgrounds primarily in Physics and AI, bringing together expertise from AWS, Meta, IBM, Nvidia, Xanadu, and leading academic institutions. This interdisciplinary team is uniquely positioned to pioneer the unified approach to Physics and AI pursued at Extropic.

A Stellar Lineup of Backers
Extropic is thrilled to announce the successful closure of its Series Seed round, raising $14.1 million. Leading the investment is Steve Jang and Kindred Ventures, with participation from Buckley Ventures, HOF Capital, Julian Capital, Marque VC, OSS Capital, Valor Equity Partners, Weekend Fund, and numerous other backers. The list of angel investors includes prominent figures such as Aidan Gomez, Amjad Masad, Arash Ferdowsi, Balaji Srinivasan, Naval Ravikant, and many more.

Extropic expresses gratitude to its broad base of investors for their commitment to advancing the frontiers of computing. The company looks forward to utilizing the Seed capital to accelerate the advent of its revolutionary computational paradigm.

For media inquiries, please contact:
Guillaume Verdon
[email protected]
+1 (737) 377-2770

SOURCE Extropic Corp.

Stem Cell Implants’ Pre-Osseointegrated Implants provide the ultimate solution for tooth loss. Unlike current implant procedures that often require donor sites or synthetic materials, our stem cell-based products are custom-made from a single hair follicle. A private round of pre-seed investment was completed in November 2023 and a seed round is announced.

SAN DIEGO, Dec. 12, 2023 — Stem Cell Implants Inc. today announced the completion of a private round of pre-seed investment and the initiation of its seed round. The startup raised funds to kickstart its mission to advance the field of dentistry with stem cell biotechnology.

“I am excited to bring the new frontier of regenerative medicine to the dental industry,” said Dr. Allan Dovigi DDS MS, CEO and Co-Founder of Stem Cell Implants. 

The company’s patented Pre-Osseointegrated Implant is poised to transform the industry through several key features:

1. Unlimited amounts of bone and soft tissue can be custom-made and formed in vitro for grafting.
2. No risk of immune rejection or disease transmission.
3. Quicker, more predicate stem cell-based healing.

The startup is building its team and roadmapping regulatory approval. 

About Stem Cell Implants Stem Cell Implants Inc. aims to harness the power of stem cell biotechnology to revolutionize dental implants. Founded in 2023 and based in San Diego, it envisions a new frontier of regenerative medicine in dentistry.

Visit stemcell-implants.com to learn more.

CONTACT: Marcus Dovigi, [email protected], 858-999-1197

SOURCE Stem Cell Implants, Inc.

Xeol’s technology secures an organization’s end-of-life software

NEW YORK, Dec. 12, 2023 — Xeol, the New York City-based cybersecurity company, announced today that it raised $3.2 million in Seed funding led by Shield Capital with Y Combinator and 468 Capital also participating.

Cyber attacks against private enterprises’ software supply chains multiplied sevenfold over the past 3 years. Software supply chains must be secured just as industrial supply chains are secured from components to assembly to delivery. This is becoming even more pressing as open source software use and attack surfaces widen. 

“Now is the right time to come out of stealth mode to tackle the software supply chain problem with foundational standards like Software Bill of Materials (SBOM) and Supply-chain Levels for Software Artifacts (SLSA) gaining traction,” stated Xeol CEO, ShiHan Wan. “These standards allow us to go much deeper and be much more accurate with supply chain risks like outdated software”

Xeol’s focus is to secure software throughout its lifecycle beginning at the code repository all the way through delivery to customers. The team starts by managing enterprises’ end-of-life software whose publishers no longer provide security patches. Attackers typically gain access to vulnerable systems by phishing, then exploiting unpatched software. PCI 4.0, a security standard for handling payment card data, will mandate that companies have a program to manage end-of-life software, highlighting the growing threat surface.

Since launching the company four months ago, Xeol has already signed its first Fortune 500 customer. For this customer, the team was able to identify more than 2,000 end-of-life software components and reduce the company’s exposure by 60%.

“Xeol is building the next generation of protection for the software we rely on every day to run our businesses. This software makes up a part of our national critical infrastructure and must be protected,” said Mike Brown, SHIELD partner and former Symantec CEO.

Founders

ShiHan is the co-founder and CEO of Xeol. He helped build 2 startups (Ada and Electric) from early stages to unicorn. ShiHan was previously Director of Platform Engineering at Electric responsible for application security, infrastructure security, SRE, and frontend and backend platforms. Before that ShiHan was the founding engineer at Ada building out the messaging and bot platform that handled 100M of messages a day.

Benji is the co-founder and CTO of Xeol. Benji was the first infrastructure and security engineer at AI unicorn Ada responsible for all things security, compliance, and infrastructure. Afterwards, he helped develop SRE best practices at Datadog and develop their service catalog product. His open-source tools are used by engineers at Google, Apache, and Red Hat every day.

Learn more at https://www.xeol.io/

SOURCE Xeol

Company accelerates development of its AI-powered robotically-assisted imaging solution for cardiovascular interventions and appoints seasoned medtech executive as General Manager 

LOS GATOS, Calif., Dec. 12, 2023 — Laza Medical, Inc., the latest Shifamed portfolio company, announced today that it has closed $36M in Series A financing. Laza Medical is developing an imaging solution for cardiac interventions enabled by artificial intelligence (AI) software and state-of-the-art robotics. Led by The Capital Partnership (TCP) with financial participation from GE HealthCare, PA MedTech VC fund, Unorthodox Ventures, and Dara Holdings, funds will be used to accelerate product development and further expand the team. Additionally, the company announced the appointment of seasoned medtech executive, Pablo Garcia, as General Manager.

“The closing of this significant financing round validates the large, unmet need Laza’s solution will address, and we are grateful for the strong support of our investors,” stated Amr Salahieh, Founder of Shifamed and Chairman of Laza Medical. “I am delighted to have Pablo join and lead Laza at this important time. His wealth of knowledge and expertise in both digital products and robotics will be critical as Laza drives towards its upcoming milestones.”

Mr. Garcia joins Laza as General Manager and brings over two decades of medical device development and leadership experience. Previously, he served as the Vice President of Digital Solutions for Johnson & Johnson and was the technical co-founder of Verb Surgical, a strategic venture between Google and Johnson & Johnson to develop a surgical robotics platform.  In 2020, this venture was acquired by Johnson & Johnson to be part of their medical robotics portfolio.

“I am excited to join the Laza team and look forward to advancing this comprehensive imaging solution so that interventional operators can safely and efficiently tackle complex cases,” stated Garcia. “We have assembled a strong team with expertise in robotics, software, artificial intelligence, and medical imaging, and are committed to bringing this much needed innovation to market.”

Structural heart and electrophysiology are two large and rapidly growing segments of the interventional cardiology market. Ultrasound imaging is necessary to guide these interventional cases, yet lack of resources makes it also a leading factor limiting growth. Laza aims to optimize procedural workflows and elevate the standard of imaging for these procedures. The company’s solution is designed to enable top-quality imaging and advanced procedure navigation for a broad population of clinicians through a simple user interface.

“Obtaining high quality images of the heart is critical to improving diagnostic confidence and guiding cardiac interventions,” said Dagfinn Saetre, General Manager, Cardiovascular Ultrasound, GE HealthCare. “We appreciate the opportunity to participate in this funding round for Laza Medical, who is working to pioneer innovative AI, robotics and ultrasound technology to help overcome some of the most pressing cardiac imaging challenges facing clinicians today.”

About Laza Medical, Inc.
Laza Medical is a privately held portfolio company of Shifamed, LLC., a highly specialized medical innovation hub founded by serial entrepreneur, Amr Salahieh. The company is focused on developing a high-quality AI-powered robotic imaging solution for cardiovascular interventions. For more information, visit www.lazamedical.com.

MEDIA CONTACT:
Charlene Herndon
SPRIG Consulting LLC
[email protected]

SOURCE Laza Medical, Inc.

The round led by Riot Ventures culminates a year of rapid development as the company readies its first two spacecraft for launch in 2024

CENTENNIAL, Colo., Dec. 12, 2023 — True Anomaly, Inc., the technology company developing advanced hardware and software systems to ensure the sustainable security of space, today announced it has closed a $100M Series B equity raise. The round was led by Riot Ventures with participation from Eclipse, ACME Capital, Menlo Ventures, Narya, 645 Ventures, Rocketship.vc, Champion Hill Ventures, and FiveNine Ventures. This financing enables continued investment in people, products, and services to further advance True Anomaly’s mission.

True Anomaly was founded in early 2022 by space operators and technologists who helped define the operational concepts for modern space security operations. The company builds solutions that address space domain awareness, security, and readiness challenges. This includes a differentiating combination of dynamic software applications as well as on-orbit spacecraft performing rendezvous and proximity operations (RPO) and non-Earth imaging (NEI). The company’s products and services also offer solutions for space operator training, capabilities testing, and rapid response missions.

“A responsive and agile defense industrial base is essential to provide the tools for deterrence and global security,” said Even Rogers, True Anomaly CEO and Co-Founder. “Space is the newest and most vulnerable theater of contemporary global competition, but the U.S. and its allies are ill-equipped for a conflict that begins in or extends into space. True Anomaly is solving this by building the technologies for a more secure, stable, sustainable, and transparent space environment. This Series B fundraise equips True Anomaly with the proceeds to maintain a deep focus on our mission, deliver incredible products, and continue to invest in the nation’s next strategic offset.”

In its first full year of operations, True Anomaly opened its GravityWorks spacecraft manufacturing facility in the Denver Tech Center and doubled its staff from 50 to more than 100 employees.

“We’ve had the unique privilege of working with True Anomaly since inception,” said Will Coffield, Co-Founder and General Partner at Riot Ventures. “Doubling down in this round is a reflection of the exceptional execution we’ve witnessed over the last two years. The U.S. and its allies face intense national security challenges in the space domain, and we believe True Anomaly is going to be the company that delivers the core set of capabilities to offset those threats.”

True Anomaly is also steadily expanding its Executive Leadership Team with industry expertise to help scale the business. Mark Seidel joined as Chief Financial Officer and Diana Lovati as Chief Information Security Officer in 2023.

“True Anomaly’s momentum across technology, product, and commercialization has been staggering in 2023,” said Seth Winterroth, Partner at Eclipse. “This Series B not only validates True Anomaly’s traction, but also illustrates the team’s ability to scale, execute on product delivery, and ultimately, secure their incumbency in space security.”

True Anomaly recently completed the build, assembly, and integration of its first two Jackal autonomous orbital vehicles (AOVs), which are slated to launch aboard SpaceX’s Transporter-10 mission in 2024.

For more information about True Anomaly, visit https://www.trueanomaly.space.

About True Anomaly
True Anomaly builds innovative technology at the intersection of spacecraft, software, and AI to deliver solutions for space security, sustainability, and accessibility. The company empowers the U.S. government, its allies, and partners as well as the commercial space industry to lead safe, resilient operations on orbit to secure life on Earth.

About Riot Ventures
Riot Ventures is a seed and growth stage venture capital firm dedicated to working closely with a small group of iconic companies focused on the modernization of critical industries. The firm partners with founders at the earliest stages and writes checks ranging from $1M to $100M+. For more information, visit http://riot.vc

About Eclipse
With over $4 billion in assets under management, 70-plus portfolio companies, and a team of investors with deep operating expertise in technology, manufacturing, supply chain, logistics, healthcare, defense, and consumer products, Eclipse is a leading U.S. venture capital firm. Its leadership team has the experience necessary to create and scale complex operations. Eclipse partners with exceptional companies that make physical industries more efficient, resilient, and profitable. For more information, visit www.eclipse.vc.

SOURCE True Anomaly

INDIANAPOLIS, Dec. 12, 2023 — Boomerang Ventures, a leading combination venture capital and studio firm, announced a strategic investment in Primary Record, an early-stage company developing a medical health data application. Completed in October 2023, the investment marks a milestone for Primary Record, securing $1M and a Venture Capital Investment tax credit of 30%.

Primary Record enhances the family experience of navigating healthcare through its secure mobile health app that consolidates personal health data, simplifying communication and sharing to improve care coordination while reducing costs.

“Primary Record was born from the idea that families should have the tools to own and share their health information. This investment will provide crucial support as we pursue our vision,” said Jean Ross, RN, Co-Founder, Primary Record.

Research indicates that 50%+ of the U.S. population suffers from one chronic condition, while 27%+ face multiple chronic conditions, and the prevalence of multiple chronic conditions among adults age 65+ with Medicare is 58%+. 40%+ of school-aged children live with a chronic condition. As the 21st Century Cures Act reshapes how medical data is shared, Primary Record is well-positioned to play a pivotal role in modernizing healthcare data management.

“Co-leading this deal in Primary Record alongside Render Capital presented a game-changing opportunity in personal health information management,” said Oscar Moralez, Founder & Managing Partner, Boomerang Ventures.

Primary Record’s mobile app launched on December 1, 2023, initially focused on end-users, families, and community partners. The company’s roadmap includes expanding its offerings to public and private healthcare agencies in Spring 2024.

About Boomerang Ventures

Founded in 2019, Boomerang Ventures is a venture capital firm focused on early growth-stage connected health technology companies. Leveraging a combination studio and venture fund established in 2020 and 2022, respectively, Boomerang provides the collaborative direction, deep industry expertise, and continuum of support founders need to take their innovations from ideation to market. Visit Boomerang.vc.

About Primary Record

Primary Record is a healthcare technology company on a mission to simplify medical information for families. Established in 2020, Primary Record offers a user-friendly mobile health app designed to streamline the collection, organization, and sharing of personal health data. By facilitating better communication within care teams and putting healthcare information at the fingertips of families, Primary Record aims to improve the coordination of care and reduce costs.Visit primaryrecord.com.

Media Contact:
Audra Wait
Wait & Co. (on behalf of Boomerang Ventures)
[email protected]
615-504-8812

SOURCE Boomerang Ventures

Expansion to Art Platform Used by Professional Studios To Reduce Costs and Time by Creating and Collaborating on One Digital Canvas

AUSTIN, Texas, Dec. 12, 2023 — Magma, a collaborative browser-based art creation and project management platform with more than 2 million users across 100+ countries, has closed a Seed Round of funding. The $5M raise was led by Silicon Valley-based GFR Fund, with contributions from Bandai Namco Entertainment 021 Fund, 4founders, Supernode Global, Gaingels, Anorak Ventures, Acequia Capital and leading industry angels. With the funding, innovative new features will be introduced to Magma’s all-in-one art platform that allows art teams to easily exchange ideas on one canvas, and improve output and workflows. The Round is also being used to expand the international team including key hires in operations, business development, and sales. Oli Strong has recently joined as the company’s CSO/COO and Heather Shelton was hired as the Commercial Director.

Magma is a cloud-based art collaboration platform that facilitates global creative teamwork. With Magma, teams and stakeholders can connect and collaborate from anywhere, at any time, and on any device. It is the only professional art collaboration and management tool that offers integrated version control, in-app video chat, and generative AI. As a centralized repository for project data, digital artwork, and creative ideas, Magma’s live collaborative canvas is ideal for idea development, character design, concept art, storyboarding, art reviews, onboarding and training, brainstorming, and other creative endeavors. Users enjoy complete control over the whole creative process and can leverage in-canvas tools and a management dashboard for streamlined feedback, including rapid preview, edits, storage, and easy access to all team artwork.

“Leading this Seed Round reflects our confidence in Magma as a key player in the creative and collaborative technology ecosystem,” said Teppei Tsutsui, General Partner of GFR Fund. “Magma has shown tremendous success already, with its impressive user engagement numbers, and has a leading reputation in the industry. We have been impressed with what the team has achieved to date and are excited to see them execute their vision. We are also optimistic for the way that AI might shape the creation process and expect Magma to influence how it can be carefully adopted.”

Launched by 3 founders with start-up backgrounds and supported by an international team, Magma has seen tremendous growth with 20+ million artworks created and 4+ million visits per month. Magma is trusted by industry leaders in animation studios, game development, art studios, leading creative higher education institutions, and more. Magma’s partners include Pitch Dev Studios, Virtuos, Wooga, Wacom, Seneca College, and North Carolina State University. Artists have reported remarkable benefits using Magma including:

• 25% reduction in project delivery time
• 32% less time spent in meetings
• 40% fewer revisions per cycle
• 72% increase in employee satisfaction

These benefits not only improve the quality of output and the time it takes to achieve them, but also provide dramatic cost savings.

“As artists and technologists ourselves, we put a lot of emphasis on listening to our community. We have the agility and infrastructure to build and adapt quickly to meet the needs of our users, to become the de facto cloud-based artist collaboration platform,” said Damien Kaczmarck, co-founder and CEO of Magma. “Closing this important round of funding will help us get there – not just financially, but through partnership with our targeted investors across various industries. We are fortunate to collaborate with these exceptional partners and are grateful for their support.”

Magma offers a range of pricing solutions for artists, including free offerings, collaborative professional packages, and turn-key enterprise programs. Pricing can be found here.

About Magma:
Launched in 2020, Magma is a collaborative canvas built from the ground up for artists. Created by artists for artists, Magma provides real-time creation, collaboration, communication, brainstorming, and sharing, all within a virtual canvas. The platform hosts artists in over 100 countries, with more than 2 million users contributing to the creation of over 20 million artworks. For more information, visit www.magma.com.

Resources

SOURCE Magma

Proceeds to support company in advancing its first off-the-shelf iPS-T cell therapy against GPC3+ cancers toward the clinic

Oversubscribed Series A led by EQT Life Sciences, F-Prime Capital and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative (FTI), JIC Venture Growth Investments, and D3 LLC

Carl June, M.D., pioneer of CAR-T cell therapy, appointed to Scientific Advisory Board

Licensed technology from Kyoto University and University of California, San Francisco

SAN FRANCISCO and KYOTO, Japan, Dec. 12, 2023 — Shinobi Therapeutics (Shinobi), the biotechnology company developing a new class of immune evasive iPS-T cell therapies, today announced that it has closed a $51 million Series A financing. The oversubscribed round was led by EQT Life Sciences, F-Prime Capital and Eight Roads Ventures Japan, with participation from Astellas Venture Management, Fast Track Initiative (FTI), JIC Venture Growth Investments, and D3 LLC. Shinobi will use the funds to advance its ‘Katana’ iPS-T cell therapy platform and progress its first program to treat GPC3+ solid tumor cancers toward the clinic.

“We’re thrilled to launch Shinobi out of stealth with a clear mission to develop an all-in-one solution to address some of the biggest challenges facing the cell therapy space today,” said Dan Kemp, Ph.D., Chief Executive Officer of Shinobi. “Having led several cell therapy programs at other global companies, I’ve never encountered a technology platform that is capable of advancing the field as dramatically as this.”

Cell therapies have shown remarkable promise in treating blood cancers and other intractable diseases, but manufacturing costs render these therapies inaccessible to many patients around the world. Off-the-shelf cell therapies offer a more scalable manufacturing approach, but face the additional challenge of allo-rejection, as patients’ immune systems reject donor-derived and engineered cells as foreign invaders. To overcome this immune response, patients today receive immunosuppressive drugs before treatment, which can often result in unwanted side effects and serious complications. Shinobi is taking a different approach by creating therapies that work with, not against, the patient’s immune system.

Shinobi’s unique approach uses methods developed by scientific co-founders Tobias Deuse, M.D. and Shin Kaneko, M.D., Ph.D., to first edit iPSCs to become highly immune evasive before they are differentiated with the company’s proprietary Katana technology to create CD8αβ iPS-T cells. “Shinobi’s Katana platform has the potential to make CAR-T cell therapies accessible to patients on a global scale,” said Carl June, M.D., who has been appointed to Shinobi’s Scientific Advisory Board.

“Shinobi stands alone in the growing cell therapy field by engineering the most comprehensive immune evasion technology directly into its cell products,” said Robert Weisskoff, Ph.D, Partner at F-Prime Capital. “With our colleagues at Eight Roads Ventures Japan and Donald Payan M.D., we envisioned combining the decade’s worth of iPSC research pioneered by Shin Kaneko M.D., Ph.D and developed by Yasumichi Hitoshi M.D., Ph.D. and Ryosuke Gonotsubo in Kyoto, Japan, with breakthrough immune evasion technology created by Tobias Deuse, M.D. in San Francisco. Shinobi Therapeutics is the result of these merged technologies, which delivers an allogeneic platform that effectively protects cell therapies from T cells, innate immune cells, as well as antibody-mediated immune rejection.”

“The full potential of allogeneic cell therapies will likely never be realized without overcoming the challenge of allo-rejection,” said Fouad Azzam, Ph.D., Partner at EQT Life Sciences. “Shinobi’s hypoimmune technology opens the door to a broader pipeline of off-the-shelf cell therapies far beyond T cells and oncology. We’re planning to leverage this platform in important areas of regenerative medicine and autoimmune disease.”

About Shinobi Therapeutics

Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Based on the research of scientific co-founders Shin Kaneko, M.D., Ph.D., at Kyoto University and Tobias Deuse, M.D., at University of California, San Francisco, Shinobi has created a new allogeneic CD8αβ iPS-T cell platform that demonstrates comprehensive immune evasion from all arms of the immune system. For more information, please visit www.shinobitx.com.

About EQT Life Sciences

EQT Life Sciences was formed in 2022 following an integration of LSP, a leading European life sciences and healthcare venture capital firm, into the EQT platform. As LSP, the firm raised over EUR 3.0 billion (USD 3.5 billion) and supported the growth of more than 150 companies since it started to invest over 30 years ago. With a dedicated team of highly experienced investment professionals, coming from backgrounds in medicine, science, business, and finance, EQT Life Sciences backs the smartest inventors who have ideas that could truly make a difference for patients.

More info: www.eqtgroup.com

Follow EQT on LinkedIn, Twitter, YouTube and Instagram

About F-Prime Capital

F-Prime Capital is a leading global venture capital firm investing in healthcare and technology to solve the greatest challenges in healthcare and medicine while delivering on the conviction that everyone deserves a gold standard of care.

For over 50 years and with a portfolio of nearly 300 companies and counting spread across the Americas, Europe, and Asia, our independent venture capital group combines singular and deep expertise in life science, healthcare, and technology to identify and support founders with the next big ideas in therapeutics, medtech, and healthcare IT and services. With over $4.5 billion dollars under management, our team has created or co-created over 30 companies including Denali, Beam, Innovent, and has helped build many others including Blueprint Medicines, Iora Health, PatientPing, Devoted Health and Ultragenyx. 

F-Prime is headquartered in Cambridge, MA, with offices in London, UK and San Francisco, CA. For more information, please visit www.fprimecapital.com and follow us on X and LinkedIn.

About Eight Roads Ventures

Eight Roads is a global venture capital firm backed by Fidelity, managing over $11bn of assets across offices in China, India, Japan, Europe and the US. With over 50-year history of investing in healthcare and technology, Eight Roads has partnered with more than 300 game-changing and fast-growing companies globally. At Eight Roads Ventures Japan, our strategy in biotech sector is to identify world-class science and to build a global company that will revolutionize medicine.

For more information, please visit https://eightroads.com/en/

SOURCE Shinobi Therapeutics